GI Cancer
Contact Info
-
+123+456-7890 -
sarahlee@prohealth.com
Appointment Schedules
- Monday 09.00-12.00
- Wednesday 15.00-18.00
- Friday 09.00-12.00
Dr Scott Kopetz
MD
Professor, Deputy Chair for Translational Research, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Colon Cancer Task Force, (National cancer Institute) NCI Houston, Texas USA
Degrees
-
University of California, San Francisco.
Medical degree
-
University of California, Los Angeles (UCLA) Medical Center.
Completed residency training in psychiatry
-
University of California, Berkeley.
Master of Public Health degree
Experiences
-
Worked in community mental health clinics, private practice, and academic medical centers.
-
Expertise in the treatment of mood disorders, anxiety disorders, and psychotic disorders.
-
Special interest in womens mental health and perinatal psychiatry.
-
Experience managing complex cases that involve both mental health and medical issues.
Awards/Achievements
-
Fellow of the American Psychiatric Association (FAPA).
-
Recognized for research contributions with grants from the National Institute of Mental Health (NIMH) and the American Foundation for Suicide Prevention.
Dr. Scott Kopetz received his medical degree from Johns Hopkins School of Medicine after an undergraduate degree in Electrical and Biomedical Engineering at Vanderbilt University. He obtained his residency training in Internal Medicine at Duke University Medical Center, medical oncology fellowship at M. D. Anderson Cancer Center and Ph.D. at M.D. Anderson in Cancer Biology.
Dr. Kopetz is currently Deputy Chair of the Department of Gastrointestinal Medical Oncology and Program Leader of the GI Program of the Cancer Center Support Grant at UTMDACC. Dr. Kopetz is well versed in multidisciplinary care of and translational research for GI cancer patients. His laboratory is funded by multiple NIH-funded grants. Dr Kopetz is a leader of the GI Cancer Center Support Grant at MD Anderson and the Colorectal Cancer Moonshot, a multi-disciplinary effort to improve the survival of this disease beyond incremental advances. Dr Kopetz has developed a translational and clinical trial program in BRAF-mutated colorectal cancer, which has resulted in addition of combination therapy with a BRAF inhibitor to the current treatment guidelines. He also co-lead the clinical trial resulting in the FDA-approval of nivolumab and ipilimumab for mismatch repair deficient tumors. He also is an innovator in the development and implementation of circulating tumor DNA into clinical management, including interrogation of mechanisms of resistance, evaluation of minimal residual disease, and integration into clinical trial designs.
